Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.

Inclusion Criteria: 1. Subject is in good health (as determined by medical history) 2. Subject is planning on traveling anywhere outside the US (except Canada) for at least 5 and no more than 14 days 3. Subject is scheduled to depart on their planned trip no later than 14 days and no earlier than 4 days after having blood drawn for clinical laboratory assessments and urine collected for a pregnancy test (females of childbearing potential only) Exclusion Criteria: 1. Subject has hypersensitivity or allergy to rifaximin or rifampin 2. Subject has known or suspected alcohol abuse or illicit drug use within 1 year of enrollment 3. Subject participated in an investigational drug or device study within the 30 days prior to enrollment 4. Subject received rifaximin in a previous clinical study 5. Subject received any systemic or gastrointestinal-specific antibiotic within 7 days of the first dose of study drug 6. Subject received antidiarrheal medication (eg, loperamide, lactobacillus, BSS, Kaopectate®) within 24 hours of the first dose of study drug